Evidence map›Paper›PMID 30689224›Full record

ArticleStatistics in medicine2019

Alpha spending for historical versus surveillance Poisson data with CMaxSPRT.

Ivair R Silva, Wilson M Lopes, Philipe Dias, W Katherine Yih

Open access · greenAbstract read
In one paragraph

Article in Statistics in medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 9 citations in OpenAlex.

  1. Robust Alpha Spending for Unstable Data.Statistics in medicine · 2026
    Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Ivair R SilvaDepartment of Statistics, Federal University of Ouro Preto, Brazil.ORCID 0000-0003-2701-8924
Wilson M LopesDepartment of Statistics, Federal University of Ouro Preto, Brazil.
Philipe DiasDepartment of Statistics, Federal University of Ouro Preto, Brazil.
W Katherine YihDepartment of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
Universidade Federal de Ouro Preto · BRHarvard University · US

Funding

Software for Near Real-Time Post-Market Drug and Vaccine Safety SurveillanceR01GM108999 · NIGMS · HARVARD PILGRIM HEALTH CARE, INC. · PI KULLDORFF, MARTIN · 2014 to 2017
$1.1M
NIGMS NIH HHS R01 GM108999
6 · The paper itself

Abstract

Sequential analysis hypothesis testing is now an important tool for postmarket drug and vaccine safety surveillance. When the number of adverse events accruing in time is assumed to follow a Poisson distribution, and if the baseline Poisson rate is assessed only with uncertainty, the conditional maximized sequential probability ratio test, CMaxSPRT, is a formal solution. CMaxSPRT is based on comparing monitored data with historical matched data, and it was primarily developed under a flat signaling threshold. This paper demonstrates that CMaxSPRT can be performed under nonflat thresholds too. We pose the discussion in the light of the alpha spending approach. In addition, we offer a rule of thumb for establishing the best shape of the signaling threshold in the sense of minimizing expected time to signal and expected sample size. An example involving surveillance for adverse events after influenza vaccination is used to illustrate the method.

Indexed as

Poisson DistributionAdverse Drug Reaction Reporting SystemsClinical Trials as TopicComputer SimulationHumansInfluenza VaccinesProduct Surveillance, PostmarketingSample SizeInfluenza Vaccinesclinical trialspostmarket vaccine safety surveillancesample sizetime to signal

Identifiers

PMID30689224
PMCPMC6955154
OpenAlexW2914151686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.